替吉奥单药一线治疗老年晚期胃癌的疗效和安全性研究  

Efficacy and safety of S1 as first - line treatment in elderly Patients with advanced gastric cancer

作　　者：彭平[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤中心,湖北武汉430030

出　　处：《医学美学美容（中旬刊）》2015年第5期55-55,共1页

摘　　要：目的：探讨替吉奥作为晚期老年胃癌患者一线化疗的疗效和安全性。方法：收集我科2010．2-2014．10接受替吉奥单药化疗的晚期老年胃癌患者共计62例。替吉奥单药用法为每次40mg，每天2次，连续14天，21天一个周期，连用2周期后评价疗效。结果：替吉奥单药的疾病控制率为62．9％，有效率为17．7％，主要不良反应为中性粒细胞下降，神经毒性，手足综合症，恶心，呕吐，腹泻，经对症治疗后均可好转，无治疗相关性死亡。结论：替吉奥单药治疗晚期老年胃癌效果较好，耐受性良好。Objective ：To investigate the efficacy and safety of S1 as first -line treatment in elderly patients with advanced gastric cancer Methods： Sixty -two elderly patients with advanced gastric cancer were collected from Feb 2010 to Oct 2014. All patients received S1 chemotherapy, S1 40rag was given orally, twice daily on days 1 to 14 followed by one week rest period, the cycle was repeated every three weeks. Assessment of the response was made after two cycles. Results： The disease control rate was 62.9% and the overall objective response rate was 17.7% in the S1 group. The major adverse effect in the S1 group included leucocytopenia, neuropathy, hand and foot syndrome, nause, vomiting and diarrhea. Conclusions： S1 offers an effective, safe and well -tolerated regimen for e elderly patients with gastric cancer.

关 键 词：胃癌 老年患者 S1 

分 类 号：R722.12[医药卫生—儿科]